VistaGen Therapeutics (NASDAQ: VTGN) Featured Research Report

20 A EGIS C APITAL C ORP. Fig. 9. Clinical development success rates (2006-2015) PH10(P2) PH94B (P3) VistaGen Therapeutics, Inc. October 8, 2020